Immune Pharmaceuticals reports additional Phase II data for bertilimumab in bullous pemphigoid

In September, Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) reported additional data from 6 patients with moderate to severe bullous pemphigoid in a Phase II trial showing that IV bertilimumab (CAT-213, iCo-008) led to a decline in the Bullous Pemphigoid Disease Area Index (BPDAI) Total Activity Score of 85% (p=0.0096). Additionally, bertilimumab led to a decrease in the mean BPDAI Total Activity Score from 56 at baseline to 10 by day 84, and a decrease of 72% in mean BPDAI Total Activity Score by day 42 (p=0.0145). By day 84, all 6 patients had a >50% reduction in BPDAI Total Activity Score, and 4 patients had a >90% reduction.

The initial mean prednisone dose was 0.3 mg/kg, which decreased to 0.1 mg/kg by day 84 (p=0.0014). Bertilimumab was well tolerated, with no serious adverse events reported...